Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region.
Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, Grimm RH Jr, Hansson L, Lacourcière Y, Muller JE, Sleight P, Weber MA, White WB, Williams GH, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Black HR, et al. Among authors: grandits g. J Hypertens. 2005 May;23(5):1099-106. doi: 10.1097/01.hjh.0000166853.26087.22. J Hypertens. 2005. PMID: 15834298 Clinical Trial.
Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial.
Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, Hansson L, Lacoucière Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD, Anders RJ. Black HR, et al. Among authors: grandits g. Hypertension. 2001 Jan;37(1):12-18. doi: 10.1161/01.hyp.37.1.12. Hypertension. 2001. PMID: 11208750
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Black HR, et al. Among authors: grandits g. JAMA. 2003 Apr 23-30;289(16):2073-82. doi: 10.1001/jama.289.16.2073. JAMA. 2003. PMID: 12709465 Clinical Trial.
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, Hansson L, Lacoucière Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD. Black HR, et al. Among authors: grandits g. Control Clin Trials. 1998 Aug;19(4):370-90. doi: 10.1016/s0197-2456(98)00013-0. Control Clin Trials. 1998. PMID: 9683312 Clinical Trial.
Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial.
Stamler J, Neaton JD, Cohen JD, Cutler J, Eberly L, Grandits G, Kuller LH, Ockene J, Prineas R; MRFIT Research Group. Stamler J, et al. Among authors: grandits g. J Am Heart Assoc. 2012 Oct;1(5):e003640. doi: 10.1161/JAHA.112.003640. Epub 2012 Oct 25. J Am Heart Assoc. 2012. PMID: 23316301 Free PMC article.
Regression of left ventricular hypertrophy.
Liebson PR, Grandits G, Grimm RH Jr. Liebson PR, et al. Among authors: grandits g. JAMA. 1996 Aug 21;276(7):526-7. doi: 10.1001/jama.1996.03540070022017. JAMA. 1996. PMID: 8709396 No abstract available.
Long-term cardiovascular mortality among middle-aged men with gout.
Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group. Krishnan E, et al. Among authors: grandits g. Arch Intern Med. 2008 May 26;168(10):1104-10. doi: 10.1001/archinte.168.10.1104. Arch Intern Med. 2008. PMID: 18504339
128 results